How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cushing's Disease Treatment Market
- By Treatment Type: Surgical Therapy, Pharmacological Therapy, Radiation Therapy
- By Pharmacological Therapy Type: Steroidogenesis Inhibitors, Pituitary-Directed Drugs, Glucocorticoid Receptor Antagonists
- By Surgical Approach: Transsphenoidal Surgery, Transcranial Surgery
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Surgical Therapy leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 253 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.156 →
- 11 Company Profiles 12 players: SWOT & benchmarking p.164 →
Full report · locked preview
Everything inside the Cushing's Disease Treatment Market report
A complete, evidence-based study - 11 chapters and 106 sections covering market size, segmentation across 4 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 3
Pharmacological Therapy Type 3
Surgical Approach 2
End User 3
Companies profiled
Novartis AG
Recordati S.p.A.
Strongbridge Biopharma plc
Ipsen S.A.
HRA Pharma
Pfizer Inc.
Horizon Therapeutics plc
Chiasma Inc.
Bristol-Myers Squibb Company
Eisai Co. Ltd.
Mitsubishi Tanabe Pharma Corporation
Lundbeck A/S
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Recordati S.p.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Strongbridge Biopharma plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ipsen S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →HRA Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Horizon Therapeutics plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Chiasma Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Eisai Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Mitsubishi Tanabe Pharma Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Lundbeck A/S
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,250M by 2033 · 10.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Surgical Therapy57.1
- Pharmacological Therapy15.5
- Radiation Therapy27.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,688M → $3,938M · 11.2%
Europe$1,177M → $2,504M · 9.9%
Asia Pacific$1,074M → $2,319M · 10.1%
Latin America$665.0M → $1,500M · 10.7%
Middle East and Africa$511.6M → $1,227M · 11.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.312026
10.322027
10.332028
10.342029
10.352030
10.372031
10.372032
10.382033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG14.4
- Recordati S.p.A.30.2
- Strongbridge Biopharma plc8.9
- Ipsen S.A.6.7
- HRA Pharma4.4
- Pfizer Inc.7.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type18.6%
Pharmacological Therapy Type28.3%
Surgical Approach27.3%
End User25.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.3
- Europe21.8
- Asia Pacific20.2
- Latin America13.1
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 81 | 94 | 92 | 95 | 90 | 76 | 88 |
| Recordati S.p.A. | 80 | 75 | 86 | 85 | 92 | 90 | 85 |
| Strongbridge Biopharma plc | 64 | 87 | 74 | 77 | 83 | 73 | 76 |
| Ipsen S.A. | 57 | 81 | 58 | 62 | 74 | 64 | 66 |
| HRA Pharma | 57 | 75 | 69 | 62 | 62 | 64 | 65 |
| Pfizer Inc. | 46 | 59 | 51 | 46 | 46 | 59 | 51 |
| Horizon Therapeutics plc | 50 | 44 | 47 | 50 | 46 | 44 | 47 |
| Chiasma Inc. | 60 | 56 | 47 | 38 | 40 | 39 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Recordati S.p.A.
- Strongbridge Biopharma plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Recordati S.p.A. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Strongbridge Biopharma plc | − | ◐ | ✓ | ◐ | ◐ | ◐ |
| Ipsen S.A. | ◐ | ✓ | − | ◐ | ✓ | ◐ |
| HRA Pharma | − | − | − | ◐ | − | ◐ |
| Pfizer Inc. | − | ◐ | − | − | − | ◐ |
| Horizon Therapeutics plc | − | − | − | ◐ | ◐ | − |
| Chiasma Inc. | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG88
2Recordati S.p.A.85
3Strongbridge Biopharma plc76
4Ipsen S.A.66
5HRA Pharma65
6Pfizer Inc.51
7Horizon Therapeutics plc47
8Chiasma Inc.47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGRecordati S.p.A.
Challenger1
Strong scale, closing on the leaders.
Strongbridge Biopharma plc
Contender2
Focused players with pockets of strength.
Ipsen S.A.HRA Pharma
Niche3
Specialists in a single segment or region.
Pfizer Inc.Horizon Therapeutics plcChiasma Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Cushing's Disease Treatment Market — a $586M beachhead inside a $9.83B market.
Beachhead (SOM)$586Mobtainable near-term
Serviceable (SAM)$4.07Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Surgical Therapy
Best fit — highest urgency & budget in Treatment Type.
Economic buyer75 fit
Pharmacological Therapy
Strong fit — clear ROI and a fast path to value.
End user70 fit
Radiation Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Pharmacological Therapy Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Surgical Approach
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cushing's Disease Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified21%
Evaluation11%
Closed-won6%
$12.2KCAC
$53KLTV
4.4:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cushing's Disease Treatment Market is a durable-growth opportunity — $2.89B by 2033, compounding at 9.2%.
TAM · 2025$1.44Btoday
TAM · 2033$2.89Bforecast
CAGR9.2%2027–2033
Cumulative$18.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.89BTotal addressable market
SAM$1.04BServiceable available market
SOM$207MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.2% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.89BLarge & growingTAM by 2033 at 9.2% CAGR
$1.04BServiceable nowreachable with today’s model
$207MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.26BBear6.0% CAGR
$2.89BBase9.2% CAGR
$3.70BBull12.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Pharmacological Therapy Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cushing's Disease Treatment Market — a $6.72B market by 2033. Plan: grow share from 6.8% to 12.3%.
Market size · 2033$6.72Btotal addressable
Market CAGR5.5%2027–2033
Target share12.3%from 6.8% today
Revenue ambition$826Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 12.3% | On track |
| Revenue | $487M | $826M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 28.1% | 45.0% | Ahead |
| Customer retention | 87.6% | 95.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Pharmacological Therapy Type capability
A defensible second engine — invest in Pharmacological Therapy Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Pharmacological Therapy Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $98M capacity & capability investment
- Greenlight bolt-on M&A in Pharmacological Therapy Type
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cushing's Disease Treatment Market conversation — a $7.45B market you can size, segment and defend in minutes.
Market size · 2033$7.45Btotal opportunity
Growth4.4%CAGR to 2033
Addressable buyers1,032+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 3 mopayback period
$60K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Novartis AGRecordati S.p.A.Strongbridge Biopharma plcIpsen S.A.HRA PharmaPfizer Inc.Horizon Therapeutics plcChiasma Inc.+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cushing's Disease Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cushing's Disease Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Custom Procedure Trays Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportCutaneous Mastocytosis Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportCystic Fibrosis(Mucoviscoidosis)Testing Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportCystoid Macular Edema Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportCytomegalovirus Infection Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCytomegalovirus Retinitis Treatment Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportDecentralized/POC Coagulation Testing Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportDecubitus Ulcer Treatment Products Market
Market size, share, segmentation and regional forecast.
$377M market · 2025 base year
View reportIndustrial Prescription Safety Glasses Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportDeformity Spinal System Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportDengue Testing Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportDental Anaesthetic Delivery System Market
Market size, share, segmentation and regional forecast.
$687M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.